Clinical Trial: A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease

U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07778667) titled 'A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease' on Aug. 18.

Brief Summary: The purpose of this clinical trial is to learn how well lucerastat works and how safe it is in untreated adult male participants with Fabry disease.

The main question this clinical trial aims to answer is:

* Does treatment with lucerastat affects the amount of globotriaosylceramide (Gb3), a fatty substance that builds up in the kidneys, in untreated adult men with Fabry disease?

This is an open-label, single-arm trial, which means that participants will know which trial medication they ...